Skip to main content

Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.

Publication ,  Journal Article
Spasojevic, I; da Costa, LRS; Horwitz, ME; Long, GD; Sullivan, KM; Chute, JP; Gasparetto, C; Morris, A; Chao, NJ; Rizzieri, DA
Published in: Cancer Invest
November 2012

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

November 2012

Volume

30

Issue

9

Start / End Page

679 / 682

Location

England

Related Subject Headings

  • Transplantation Conditioning
  • Therapeutic Equivalency
  • Tandem Mass Spectrometry
  • Oncology & Carcinogenesis
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Chromatography, Liquid
  • Busulfan
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Spasojevic, I., da Costa, L. R. S., Horwitz, M. E., Long, G. D., Sullivan, K. M., Chute, J. P., … Rizzieri, D. A. (2012). Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest, 30(9), 679–682. https://doi.org/10.3109/07357907.2012.726386
Spasojevic, Ivan, Ligia R. S. da Costa, Mitchell E. Horwitz, Gwynn D. Long, Keith M. Sullivan, John P. Chute, Cristina Gasparetto, Ashley Morris, Nelson J. Chao, and David A. Rizzieri. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.Cancer Invest 30, no. 9 (November 2012): 679–82. https://doi.org/10.3109/07357907.2012.726386.
Spasojevic I, da Costa LRS, Horwitz ME, Long GD, Sullivan KM, Chute JP, et al. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012 Nov;30(9):679–82.
Spasojevic, Ivan, et al. “Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry.Cancer Invest, vol. 30, no. 9, Nov. 2012, pp. 679–82. Pubmed, doi:10.3109/07357907.2012.726386.
Spasojevic I, da Costa LRS, Horwitz ME, Long GD, Sullivan KM, Chute JP, Gasparetto C, Morris A, Chao NJ, Rizzieri DA. Mini test dose of intravenous busulfan (busulfex(®)) in allogeneic non-myeloablative stem cell transplantation, followed by liquid chromatography tandem-mass spectrometry. Cancer Invest. 2012 Nov;30(9):679–682.

Published In

Cancer Invest

DOI

EISSN

1532-4192

Publication Date

November 2012

Volume

30

Issue

9

Start / End Page

679 / 682

Location

England

Related Subject Headings

  • Transplantation Conditioning
  • Therapeutic Equivalency
  • Tandem Mass Spectrometry
  • Oncology & Carcinogenesis
  • Humans
  • Hematopoietic Stem Cell Transplantation
  • Chromatography, Liquid
  • Busulfan
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis